Square Pharmaceuticals (SQURPHARMA) investor relations material

Executive summary

• Consolidated net revenue for the nine months ended 31 March 2026 rose to Tk. 65.08 billion, up from Tk. 57.85 billion year-over-year, reflecting strong recovery and growth momentum after a prior slowdown.

• Net profit attributable to equity holders increased to Tk. 20.64 billion from Tk. 18.75 billion year-over-year, with EPS rising to Tk. 23.29 from Tk. 21.15.

• Standalone net revenue reached Tk. 49.89 billion, up from Tk. 45.31 billion, and standalone EPS increased to Tk. 14.45 from Tk. 13.11.

Financial highlights

• Consolidated gross profit for the nine months was Tk. 31.93 billion, up from Tk. 27.50 billion year-over-year.

• Operating profit rose to Tk. 18.74 billion from Tk. 16.32 billion, and profit before tax reached Tk. 23.00 billion, up from Tk. 19.87 billion.

• Net operating cash flow per share (NOCFPS) increased to Tk. 17.54 from Tk. 11.90 year-over-year.

• Net asset value (NAV) per share rose to Tk. 169.79 from Tk. 157.88.

• Standalone NOCFPS was Tk. 16.22, up from Tk. 10.96.

Outlook and guidance

• Management notes strong business recovery and upward momentum in revenue, with both EPS and NOCFPS showing healthy growth.

• No significant post-period events requiring disclosure.